Rock Springs Capital SPRB Position
ExitedRock Springs Capital exited their position in SPRUCE BIOSCIENCES, INC. (SPRB) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
Short interest stands at 10.0% of float with 2.8 days to cover, indicating significant bearish positioning against the stock.
About SPRUCE BIOSCIENCES, INC.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Full company profile →Short Interest
10.0%
2.8 days to cover
Rock Springs Capital SPRB Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -2,609,125 | $0 |
| Q1 2025 | Held | 2,609,125 | — | $757K |
| Q4 2024 | Held | 2,609,125 | — | $1.1M |
| Q3 2024 | Held | 2,609,125 | — | $1.2M |
| Q2 2024 | Held | 2,609,125 | — | $1.4M |
| Q1 2024 | Held | 2,609,125 | — | $2.1M |
| Q4 2023 | Decreased | 2,609,125 | -119,000 | $7.6M |
| Q3 2023 | Held | 2,728,125 | — | $6.2M |
| Q2 2023 | Held | 2,728,125 | — | $5.9M |
| Q1 2023 | New | 2,728,125 | +2,728,125 | $6.0M |
Frequently Asked Questions
Does Rock Springs Capital own SPRB?
No. Rock Springs Capital exited their position in SPRUCE BIOSCIENCES, INC. (SPRB) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own SPRB?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in SPRB.
When did Rock Springs Capital first buy SPRB?
Rock Springs Capital's position in SPRB was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's SPRB position increasing or decreasing?
Rock Springs Capital completely exited their SPRB position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SPRBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →